Gary Nachman
Stock Analyst at Raymond James
(2.53)
# 1,283
Out of 4,479 analysts
74
Total ratings
55.74%
Success rate
-3.67%
Average return
Main Sectors:
22 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Reinstates: Market Perform | n/a | $310.77 | - | 1 | Mar 28, 2024 | |
| SRRK Scholar Rock Holding | Initiates: Strong Buy | $30 | $7.63 | +293.18% | 4 | Mar 28, 2024 | |
| AQST Aquestive Therapeutics | Initiates: Outperform | $7 | $2.42 | +189.26% | 1 | Mar 28, 2024 | |
| VERU Veru Inc. | Initiates: Outperform | $3 | $0.95 | +214.60% | 1 | Mar 28, 2024 | |
| ABBV AbbVie | Maintains: Outperform | $181 → $189 | $165.96 | +13.88% | 12 | Feb 6, 2024 | |
| PCRX Pacira BioSciences | Initiates: Outperform | $42 | $22.74 | +84.70% | 9 | Dec 20, 2023 | |
| ALNY Alnylam Pharmaceuticals | Initiates: Outperform | $208 | $247.61 | -16.00% | 5 | Sep 29, 2023 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Market Perform | n/a | $105.09 | - | 7 | Sep 29, 2023 | |
| SDGR Schrödinger | Maintains: Outperform | $78 → $67 | $20.33 | +229.56% | 3 | Aug 3, 2023 | |
| AMRX Amneal Pharmaceuticals | Maintains: Market Perform | $5 → $4 | $6.54 | -38.84% | 2 | Mar 3, 2023 | |
| PHAT Phathom Pharmaceuticals | Maintains: Outperform | $35 → $30 | $10.25 | +192.68% | 4 | Mar 1, 2023 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $70 → $67 | $45.14 | +48.43% | 2 | Feb 23, 2023 | |
| ABCL AbCellera Biologics | Maintains: Outperform | $40 → $32 | $2.77 | +1,055.23% | 1 | Feb 22, 2023 | |
| VTRS Viatris | Downgrades: Market Perform | $16 → $14 | $10.43 | +34.23% | 2 | Feb 17, 2023 | |
| OPTN OptiNose | Maintains: Outperform | $6 → $5 | $1.04 | +380.77% | 3 | Nov 14, 2022 | |
| SAGE Sage Therapeutics | Maintains: Market Perform | $43 → $40 | $10.82 | +269.69% | 6 | Nov 9, 2022 | |
| TEVA Teva Pharmaceutical | Maintains: Market Perform | $11 → $10 | $16.55 | -39.58% | 1 | Nov 7, 2022 | |
| RIGL Rigel Pharmaceuticals | Maintains: Outperform | $4 → $3 | $8.42 | -64.37% | 2 | Nov 4, 2022 | |
| PYPD PolyPid | Maintains: Outperform | $810 → $750 | $4.00 | +18,650.00% | 2 | Aug 11, 2022 | |
| BHC Bausch Health Companies | Maintains: Market Perform | $15 → $8 | $7.11 | +12.52% | 2 | Aug 10, 2022 | |
| SCPH scPharmaceuticals | Maintains: Outperform | n/a | $4.21 | - | 2 | Jun 14, 2018 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Market Perform | n/a | $37.58 | - | 2 | Mar 13, 2018 |
Amgen
Mar 28, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $310.77
Upside: -
Scholar Rock Holding
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $7.63
Upside: +293.18%
Aquestive Therapeutics
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $2.42
Upside: +189.26%
Veru Inc.
Mar 28, 2024
Initiates: Outperform
Price Target: $3
Current: $0.95
Upside: +214.60%
AbbVie
Feb 6, 2024
Maintains: Outperform
Price Target: $181 → $189
Current: $165.96
Upside: +13.88%
Pacira BioSciences
Dec 20, 2023
Initiates: Outperform
Price Target: $42
Current: $22.74
Upside: +84.70%
Alnylam Pharmaceuticals
Sep 29, 2023
Initiates: Outperform
Price Target: $208
Current: $247.61
Upside: -16.00%
Jazz Pharmaceuticals
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $105.09
Upside: -
Schrödinger
Aug 3, 2023
Maintains: Outperform
Price Target: $78 → $67
Current: $20.33
Upside: +229.56%
Amneal Pharmaceuticals
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $6.54
Upside: -38.84%
Phathom Pharmaceuticals
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $10.25
Upside: +192.68%
Ionis Pharmaceuticals
Feb 23, 2023
Maintains: Outperform
Price Target: $70 → $67
Current: $45.14
Upside: +48.43%
AbCellera Biologics
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $2.77
Upside: +1,055.23%
Viatris
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $10.43
Upside: +34.23%
OptiNose
Nov 14, 2022
Maintains: Outperform
Price Target: $6 → $5
Current: $1.04
Upside: +380.77%
Sage Therapeutics
Nov 9, 2022
Maintains: Market Perform
Price Target: $43 → $40
Current: $10.82
Upside: +269.69%
Teva Pharmaceutical
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $16.55
Upside: -39.58%
Rigel Pharmaceuticals
Nov 4, 2022
Maintains: Outperform
Price Target: $4 → $3
Current: $8.42
Upside: -64.37%
PolyPid
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $4.00
Upside: +18,650.00%
Bausch Health Companies
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $7.11
Upside: +12.52%
scPharmaceuticals
Jun 14, 2018
Maintains: Outperform
Price Target: n/a
Current: $4.21
Upside: -
Amphastar Pharmaceuticals
Mar 13, 2018
Maintains: Market Perform
Price Target: n/a
Current: $37.58
Upside: -